Pfizer (PFE) stock dipped early Tuesday even after the company hiked its 2025 profit guidance, as third-quarter sales and earnings both toppled year over year.
During the September quarter, Pfizer earned an adjusted 87 cents per share, which was 38% ahead of the Street’s forecast for 63 cents, Leerink Partners analyst David Risinger. But the company only hiked its full-year earnings outlook by 3% to $3 to $3.15 a share.
“Note, PFE EPS beat consensus by $0.24 in 3Q25 but raised full-year EPS guidance by $0.08, which may be conservative,” he said in a report.
Pfizer stock dipped nearly 1% to 24.48 in premarket trades on today’s stock market.
Shares broke out of a flat base with a buy point at 26.11 in early October, after Pfizer inked a deal to participate in the direct-to-consumer drug prices website, TrumpRx.
But shares sank as much as 7% below their entry in mid-October, triggering a sell rule. Savvy investors are encouraged to cut their losses when a stock falls 7% to 8% below its entry.
Pfizer Stock: Declining Sales, Earnings
Sales also topped expectations at $16.65 billion. Analysts called for $16.51 billion, according to FactSet.
But sales fell 6% year over year, while earnings tumbled 18%. Revenue from the biggest division, global biopharmaceuticals, declined 6% on a strict, as-reported basis to $16.31 billion.
Pfizer CentreOne and Pfizer Ignite were split. CentreOne, a contract development and manufacturing business, brought in $344 million, up 21%. But PfizerIgnite didn’t generate any sales, down from $25 million in the year-earlier period. PfizerIgnite is a research, development and manufacturing arm.
In the biopharma business, oncology sales topped forecasts while revenue from Covid drug Paxlovid came up short, Leerink’s Risinger said.
Pfizer maintained its sales guidance for the year at $61 billion to $63 billion.
Risinger has a market perform rating on Pfizer stock.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
How Idexx Laboratories Business Shook Off Bears And Hit A Record
Uniqure Plummets On A ‘Confusing’ And ‘Unexpected’ Twist For Its Gene Therapy
Want More IBD Insights? Subscribe To Our Investing Podcast!
Options Trading: How To Start Using Options, How To Manage Risk
Find The Best Long-Term Investments With IBD Long-Term Leaders
